© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Conatus Pharmaceuticals’ study of emricasan for non-alcoholic steatohepatitis found the drug had no significant impact.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
